FDA Approves Lifileucel, the First Cellular Therapy for Unresectable or Metastatic Melanoma
The Dermatology Digest
FEBRUARY 20, 2024
Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors. “The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options.”
Let's personalize your content